Cargando…

Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results

With the advent of combined immunotherapies, personalized dendritic cell (DC)-based vaccination could integrate the current standard of care for the treatment of a large variety of tumors. Due to their proficiency at antigen presentation, DC are key coordinators of the innate and adaptive immune sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mastelic-Gavillet, Beatris, Balint, Klara, Boudousquie, Caroline, Gannon, Philippe O., Kandalaft, Lana E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470191/ https://www.ncbi.nlm.nih.gov/pubmed/31031762 http://dx.doi.org/10.3389/fimmu.2019.00766

Ejemplares similares

Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine
por: Boudousquié, Caroline, et al.
Publicado: (2020)

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
por: Bassani-Sternberg, Michal, et al.
Publicado: (2019)

Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy
por: Mastelic-Gavillet, Beatris, et al.
Publicado: (2023)

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
por: Sarivalasis, Apostolos, et al.
Publicado: (2019)

A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner
por: Auderset, Floriane, et al.
Publicado: (2020)

Neonatal T Follicular Helper Cells Are Lodged in a Pre-T Follicular Helper Stage Favoring Innate Over Adaptive Germinal Center Responses
por: Mastelic-Gavillet, Beatris, et al.
Publicado: (2019)

Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation
por: Auderset, Floriane, et al.
Publicado: (2019)

Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
por: Jonny, Jonny, et al.
Publicado: (2022)

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility
por: Van Nuffel, An M. T., et al.
Publicado: (2019)

Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan
por: Vono, Maria, et al.
Publicado: (2018)

Dendritic cell activation and cytokine response in vaccine breakthrough TBE patients after in vitro stimulation with TBEV
por: Marušić, Miša, et al.
Publicado: (2023)

C-type lectin receptor agonists elicit functional IL21-expressing Tfh cells and induce primary B cell responses in neonates
por: Vono, Maria, et al.
Publicado: (2023)

A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
por: Harari, Alexandre, et al.
Publicado: (2021)

IL-22 Protects Against Liver Pathology and Lethality of an Experimental Blood-Stage Malaria Infection
por: Mastelic, Béatris, et al.
Publicado: (2012)

IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors
por: Yakkala, Chakradhar, et al.
Publicado: (2019)

Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
por: Søraas, Arne, et al.
Publicado: (2022)

Breakthrough of glycobiology in the 21st century
por: Mahara, Gehendra, et al.
Publicado: (2023)

Erratum: Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
Publicado: (2023)

Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants
por: Hu, Ye-Fan, et al.
Publicado: (2022)

Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia
por: Chang, Lauren A., et al.
Publicado: (2023)

Neoantigen: A New Breakthrough in Tumor Immunotherapy
por: Zhang, Zheying, et al.
Publicado: (2021)

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2018)

Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer
por: Ahmed, Ritaparna, et al.
Publicado: (2023)

Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections
por: Ahmed, Mohamed Ibraheem Mahmoud, et al.
Publicado: (2022)

Metabolic Control of Dendritic Cell Activation and Function: Recent Advances and Clinical Implications
por: Everts, Bart, et al.
Publicado: (2014)

Immunosuppression Reversal Nanovaccines Substituting Dendritic Cells for Personalized Cancer Immunotherapy
por: Chen, Hu, et al.
Publicado: (2022)

Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
por: Paniskaki, Krystallenia, et al.
Publicado: (2022)

Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
por: Duarte, Luisa F., et al.
Publicado: (2021)

Disruption of IL-21 Signaling Affects T Cell-B Cell Interactions and Abrogates Protective Humoral Immunity to Malaria
por: Pérez-Mazliah, Damián, et al.
Publicado: (2015)

Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections
por: Ahmad, Liyana
Publicado: (2021)

Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform
por: Ahmed, Rita, et al.
Publicado: (2020)

Dendritic Cell-Targeted Vaccines
por: Cohn, Lillian, et al.
Publicado: (2014)

A 680,000-person megastudy of nudges to encourage vaccination in pharmacies
por: Milkman, Katherine L., et al.
Publicado: (2022)

Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma
por: Yakkala, Chakradhar, et al.
Publicado: (2021)

Editorial: Recent Breakthrough in Gluten Contamination
por: Verma, Anil K., et al.
Publicado: (2021)

Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses
por: Buscot, Matthieu, et al.
Publicado: (2023)

Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2–inactivated vaccine
por: He, Xiaomeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fe1mefn0g7co8gu0di8fva1t8n